Mycophenolate mofetil for treatment of idiopathic nephrotic syndrome – a single center experience (preliminary study)

Journal Title: Progress in Health Sciences - Year 2014, Vol 4, Issue 1

Abstract

Introduction: Mycophenolate mofetil (MMF) is used in treatment of idiopathic nephrotic syndrome in children (INS). Purpose: To evaluate clinical results of MMF treatment in steroid-dependent (SD) and steroid-resistant (SR) nephrotic syndrome. Materials and methods: A retrospective analysis of 26 patients (19 boys, 7 girls) with SDINS and SRINS treated with MMF during the years 2003–2013 was made. The remission length of INS and number of relapses per year before the introduction of MMF and after 12 months was calculated. An analysis of the side effects was made. Results: The median age of INS diagnosis was 26.5 months (IQRs 24-36 months). Nineteen of the patients (73%) suffered from SDINS whereas the remaining 7 (27%) had SRINS. Twenty three (88.5%) patients underwent renal biopsy: minimal change disease (MCD) in 69.6% (n=16), focal segmental glomerulosclerosis (FSGS) in 17.4% (n=4), membranoproliferative glomerulonephritis (MPGN) in 8.7% (n=2) and mesangial cell proliferation in one case. The median MMF dosage was 956.0 mg/m2/24h (IQRs 768.1-1059.7 mg/m2/24h). Eleven patients (42.3%) were taking MMF together with cyclosporine A (CsA). In patients suffering from SDINS, there was a trend to lower the recurrence rate during MMF treatment [2.0/year (IQRs 0.25-2.0 per year) vs 2.0/year (IQRs 1.0-2.75 per year), p=0.09]. Remission without proteinuria was significantly longer in patients treated with MMF; remission median was 8.5 month (IQRs 6.25-11.0 month) vs 4.5 month (IQRs 4.0-7.5 month), (p=0.014), similarly the average length of remission without corticosteroids was 6.0 months (IQRs 0.25-8.5 months) vs 3.0 months (IQRs 0.0-7.25) months (p=0.028). In children SRINS, 4/7 children MMF treatment was clinically ineffective. Side effects of the treatment were: leucopenia (n =10), hyperbilirubinemia (n = 3), gastrointestinal disorders (n = 1) and anemia (n = 1). Conclusion: This study confirmed the efficacy of the treatment with MMF in SDINR in comparison with previously used drugs, with a small number of side effects.

Authors and Affiliations

Tomczyk D. , Jander A. , Mihailescu J. , Tkaczyk M.

Keywords

Related Articles

 An ergonomic assessment and fitness evaluation of young male tea factory workers in Dooars, West Bengal

 Introduction: There are very few published reports on the heath status of tea garden workers of West Bengal, while reports on cardiorespiratory fineness and body composition of male tea factory workers is almost sc...

Computational simulation of pressure changes during embryo transfer

Purpose: The embryo transfer into the uterus by a transcervical catheter is the final stage of in-vitro fertilization procedure. This study was designed to analyze the influence of injection speed on pressure fluctuation...

The importance of the Mediterranean diet in cardiovascular disease

The Mediterranean diet is characterized by abundance of plant foods, such as vegetables, fruit, bread and cereal products, legumes, nuts and seeds, as well as olive oil, herbs and spices. Moreover, moderate intakes of da...

 Neurologic adverse events following vaccination

 The present review summarizes data on neurological adverse events following vaccination in the relation to intensity, time of onset, taking into account the immunological and non-immunological mechanisms. The autho...

Helicobacter pylori infection in North-East Poland between 1996 and 2011 on the base of histological examination

<b>Purpose</b>: The aim of the study was to conduct a 15- year (1996-2011) observations on the frequency of <i>Helicobacter pylori</i> stomach infection in patients having performed gastroscopy in the Endoscopy Unit Dist...

Download PDF file
  • EP ID EP116052
  • DOI -
  • Views 94
  • Downloads 0

How To Cite

Tomczyk D. , Jander A. , Mihailescu J. , Tkaczyk M. (2014). Mycophenolate mofetil for treatment of idiopathic nephrotic syndrome – a single center experience (preliminary study). Progress in Health Sciences, 4(1), 61-67. https://europub.co.uk./articles/-A-116052